NI201700060A - Agonistas parciales del receptor de insulina - Google Patents
Agonistas parciales del receptor de insulinaInfo
- Publication number
- NI201700060A NI201700060A NI201700060A NI201700060A NI201700060A NI 201700060 A NI201700060 A NI 201700060A NI 201700060 A NI201700060 A NI 201700060A NI 201700060 A NI201700060 A NI 201700060A NI 201700060 A NI201700060 A NI 201700060A
- Authority
- NI
- Nicaragua
- Prior art keywords
- insulin receptor
- receptor agonists
- partial insulin
- partial
- insulin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/62—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Abstract
Se divulgan dimeros de insulina y dimeros de análogo de insulina que actúan como agonistas parciales en el receptor de insulina.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462082857P | 2014-11-21 | 2014-11-21 | |
| US201562242503P | 2015-10-16 | 2015-10-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI201700060A true NI201700060A (es) | 2017-07-18 |
Family
ID=54838417
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI201700060A NI201700060A (es) | 2014-11-21 | 2017-05-19 | Agonistas parciales del receptor de insulina |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US10017556B2 (es) |
| EP (4) | EP3660041B1 (es) |
| JP (5) | JP6484337B2 (es) |
| KR (2) | KR102101136B1 (es) |
| CN (2) | CN108064173B (es) |
| AR (1) | AR102712A1 (es) |
| AU (3) | AU2015349890B2 (es) |
| BR (3) | BR122024000903A2 (es) |
| CA (2) | CA2966765C (es) |
| CL (3) | CL2017001288A1 (es) |
| CO (1) | CO2017004976A2 (es) |
| CR (1) | CR20170208A (es) |
| DO (1) | DOP2017000124A (es) |
| EA (1) | EA036714B1 (es) |
| ES (1) | ES2946247T3 (es) |
| GT (1) | GT201700104A (es) |
| IL (1) | IL252257A0 (es) |
| MX (3) | MX2017006651A (es) |
| NI (1) | NI201700060A (es) |
| PE (1) | PE20170957A1 (es) |
| PH (1) | PH12017500935A1 (es) |
| SG (4) | SG11201704064TA (es) |
| SV (1) | SV2017005445A (es) |
| TN (1) | TN2017000178A1 (es) |
| TW (1) | TW201625673A (es) |
| WO (1) | WO2016081670A2 (es) |
| ZA (1) | ZA201703238B (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20170682A1 (es) | 2014-08-04 | 2017-06-15 | Nuevolution As | Derivados de pirimidina sustituidos con heterociclilo opcionalmente condensados utiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncologicas y autoinmunitarias |
| CA2966765C (en) | 2014-11-21 | 2020-04-14 | Merck Sharp & Dohme Corp. | Insulin receptor partial agonists |
| AR105616A1 (es) | 2015-05-07 | 2017-10-25 | Lilly Co Eli | Proteínas de fusión |
| EP3922260A3 (en) * | 2016-05-24 | 2022-06-15 | Merck Sharp & Dohme Corp. | Insulin receptor partial agonists and glp-1 analogues |
| EP3463413A4 (en) * | 2016-05-25 | 2020-03-04 | Merck Sharp & Dohme Corp. | PARTIAL INSULIN RECEPTOR AGONISTS |
| CN109891237B (zh) * | 2016-10-24 | 2022-08-23 | 诺和诺德股份有限公司 | 胰岛素制剂的生物测定法 |
| AU2018317810A1 (en) | 2017-08-17 | 2020-03-19 | Novo Nordisk A/S | Novel acylated insulin analogues and uses thereof |
| JP2021533200A (ja) | 2018-08-02 | 2021-12-02 | ダイン セラピューティクス, インコーポレーテッドDyne Therapeutics, Inc. | 顔面・肩甲・上腕筋ジストロフィーを処置するための筋標的化複合体およびそれらの使用 |
| KR20210081322A (ko) | 2018-08-02 | 2021-07-01 | 다인 세라퓨틱스, 인크. | 근육 표적화 복합체 및 디스트로핀병증을 치료하기 위한 그의 용도 |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| CN112898172B (zh) * | 2019-12-04 | 2022-05-31 | 中国科学院大连化学物理研究所 | 可被羧肽酶酶解的双亲和功能团化合物的合成方法 |
| EP4076657A1 (en) | 2019-12-20 | 2022-10-26 | Nuevolution A/S | Compounds active towards nuclear receptors |
| US11613532B2 (en) | 2020-03-31 | 2023-03-28 | Nuevolution A/S | Compounds active towards nuclear receptors |
| US11780843B2 (en) | 2020-03-31 | 2023-10-10 | Nuevolution A/S | Compounds active towards nuclear receptors |
| JP2023540746A (ja) * | 2020-09-03 | 2023-09-26 | ダイン セラピューティクス，インコーポレーテッド | タンパク質－オリゴヌクレオチド複合体の調製方法 |
| EP4210729A2 (en) * | 2020-09-09 | 2023-07-19 | Merck Sharp & Dohme LLC | Insulin receptor partial agonists |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11931421B2 (en) | 2022-04-15 | 2024-03-19 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating myotonic dystrophy |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1381273A (en) * | 1971-01-28 | 1975-01-22 | Nat Res Dev | Insulin derivatives |
| US3907763A (en) | 1972-03-01 | 1975-09-23 | Bayer Ag | Insulin derivatives crosslinked by a dicarboxylic acid moiety |
| PH25772A (en) | 1985-08-30 | 1991-10-18 | Novo Industri As | Insulin analogues, process for their preparation |
| US5514646A (en) | 1989-02-09 | 1996-05-07 | Chance; Ronald E. | Insulin analogs modified at position 29 of the B chain |
| US5304473A (en) | 1991-06-11 | 1994-04-19 | Eli Lilly And Company | A-C-B proinsulin, method of manufacturing and using same, and intermediates in insulin production |
| AU1272295A (en) | 1993-12-17 | 1995-07-03 | Novo Nordisk A/S | Proinsulin-like compounds |
| CA2223272A1 (en) | 1995-05-05 | 1996-11-07 | Ronald Eugene Chance | Single chain insulin with high bioactivity |
| AU4672699A (en) | 1998-06-08 | 1999-12-30 | Theravance, Inc. | Novel sodium channel drugs and uses |
| DE19908041A1 (de) * | 1999-02-24 | 2000-08-31 | Hoecker Hartwig | Kovalent verbrückte Insulindimere |
| KR100449454B1 (ko) | 2000-10-02 | 2004-09-21 | 이현철 | 단일사슬 인슐린 유도체의 유전자를 포함하는 당뇨병치료용 벡터 |
| US6852694B2 (en) | 2001-02-21 | 2005-02-08 | Medtronic Minimed, Inc. | Stabilized insulin formulations |
| US7105314B2 (en) | 2001-04-02 | 2006-09-12 | Novo Nordisk A/S | Method for making human insulin precursors |
| US7375234B2 (en) | 2002-05-30 | 2008-05-20 | The Scripps Research Institute | Copper-catalysed ligation of azides and acetylenes |
| KR100507796B1 (ko) | 2003-04-03 | 2005-08-17 | 한미약품 주식회사 | 생체내 반감기가 증가된 ｐｅｇ-생리활성 폴리펩티드 동종이량체 결합체 및 이의 제조방법 |
| EP1692168B1 (en) | 2003-12-03 | 2011-07-20 | Novo Nordisk A/S | Single-chain insulin |
| EP1807105A2 (en) | 2004-10-27 | 2007-07-18 | Novo Nordisk A/S | Insulin receptor binding peptides with non-insulin gene activation profiles and uses thereof |
| ES2545533T3 (es) | 2004-11-01 | 2015-09-11 | The Regents Of The University Of California | Composiciones y métodos para modificación de biomoléculas |
| US20100216690A1 (en) | 2005-03-18 | 2010-08-26 | Novo Nordisk A/S | Pegylated Single-Chain Insulin |
| WO2007096332A1 (en) | 2006-02-21 | 2007-08-30 | Novo Nordisk A/S | Single-chain insulin analogues and pharmaceutical formulations thereof |
| WO2007104736A2 (en) | 2006-03-13 | 2007-09-20 | Novo Nordisk A/S | Acylated single chain insulin |
| US20090069215A1 (en) | 2006-03-13 | 2009-03-12 | Novo Nordisk A/S | Acylated Single Chain Insulin |
| WO2007104734A1 (en) | 2006-03-13 | 2007-09-20 | Novo Nordisk A/S | Acylated single chain insulin |
| US20090099065A1 (en) | 2006-03-13 | 2009-04-16 | Novo Nordisk A/S | Acylated Single Chain Insulin |
| US9505823B2 (en) | 2006-08-07 | 2016-11-29 | TEV A Biopharmaceuticals USA, Inc. | Albumin-insulin fusion proteins |
| WO2008145721A2 (en) * | 2007-06-01 | 2008-12-04 | Novo Nordisk A/S | N-terminal modification of polypeptides for protection against degradation by aminopeptidases |
| AU2009210570B2 (en) | 2008-01-30 | 2014-11-20 | Indiana University Research And Technology Corporation | Ester-based insulin prodrugs |
| RU2010147076A (ru) | 2008-04-22 | 2012-05-27 | Кейз Вестерн Ризев Юнивесити (Us) | Аналоги инсулина специфичные к изоформам |
| TWI394580B (zh) * | 2008-04-28 | 2013-05-01 | Halozyme Inc | 超快起作用胰島素組成物 |
| KR101939557B1 (ko) * | 2008-10-17 | 2019-01-17 | 사노피-아벤티스 도이칠란트 게엠베하 | 인슐린과 ｇｌｐ－1 효능제의 병용물 |
| WO2010080609A1 (en) | 2008-12-19 | 2010-07-15 | Indiana University Research And Technology Corporation | Amide-based insulin prodrugs |
| JP5789515B2 (ja) | 2008-12-19 | 2015-10-07 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | インスリン類似体 |
| WO2011059895A1 (en) | 2009-11-11 | 2011-05-19 | Quest Diagnostics Investments Incorporated | Hexa mutations |
| WO2011159895A2 (en) | 2010-06-16 | 2011-12-22 | Indiana University Research And Technology Corporation | Single chain insulin agonists exhibiting high activity at the insulin receptor |
| US8255297B2 (en) | 2010-07-20 | 2012-08-28 | Facebook, Inc. | Creation, redemption, and accounting in a virtual currency system |
| WO2012049307A2 (en) | 2010-10-15 | 2012-04-19 | Novo Nordisk A/S | Novel n-terminally modified insulin derivatives |
| KR20150021011A (ko) * | 2011-10-27 | 2015-02-27 | 케이스 웨스턴 리저브 유니버시티 | 초고도 농축된, 속효성 인슐린 유사체 제형 |
| JP6387008B2 (ja) * | 2012-09-26 | 2018-09-05 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | インスリンアナローグダイマー |
| US20160067212A1 (en) | 2013-03-15 | 2016-03-10 | Universite De Geneve | Use of insulin signaling antagonists, optionally in combination of transfection of non-beta cells, for inducing insulin production |
| MX366852B (es) * | 2013-10-04 | 2019-07-25 | Merck Sharp & Dohme | Conjugados de insulina sensibles a glucosa. |
| US10758636B2 (en) * | 2013-11-12 | 2020-09-01 | Centre For Probe Development And Commercialization | Residualizing linkers and uses thereof |
| EP3098235A4 (en) | 2014-01-20 | 2017-10-18 | Hanmi Pharm. Co., Ltd. | Long-acting insulin and use thereof |
| CA2966765C (en) * | 2014-11-21 | 2020-04-14 | Merck Sharp & Dohme Corp. | Insulin receptor partial agonists |
-
2015
- 2015-11-19 CA CA2966765A patent/CA2966765C/en active Active
- 2015-11-19 SG SG11201704064TA patent/SG11201704064TA/en unknown
- 2015-11-19 EP EP19211799.2A patent/EP3660041B1/en active Active
- 2015-11-19 BR BR122024000903-0A patent/BR122024000903A2/pt unknown
- 2015-11-19 SG SG10201809457YA patent/SG10201809457YA/en unknown
- 2015-11-19 BR BR112017010481A patent/BR112017010481A8/pt active Search and Examination
- 2015-11-19 BR BR122024000898-0A patent/BR122024000898A2/pt unknown
- 2015-11-19 US US14/945,461 patent/US10017556B2/en active Active
- 2015-11-19 KR KR1020197016746A patent/KR102101136B1/ko active IP Right Grant
- 2015-11-19 EP EP19211793.5A patent/EP3660040A3/en active Pending
- 2015-11-19 MX MX2017006651A patent/MX2017006651A/es unknown
- 2015-11-19 AU AU2015349890A patent/AU2015349890B2/en active Active
- 2015-11-19 AR ARP150103770A patent/AR102712A1/es unknown
- 2015-11-19 CN CN201580074165.6A patent/CN108064173B/zh active Active
- 2015-11-19 ES ES19211799T patent/ES2946247T3/es active Active
- 2015-11-19 SG SG10201809428UA patent/SG10201809428UA/en unknown
- 2015-11-19 CR CR20170208A patent/CR20170208A/es unknown
- 2015-11-19 CN CN202011335828.4A patent/CN112494656B/zh active Active
- 2015-11-19 EP EP15807730.5A patent/EP3221343B1/en active Active
- 2015-11-19 EP EP19211801.6A patent/EP3666792A3/en active Pending
- 2015-11-19 EA EA201791117A patent/EA036714B1/ru unknown
- 2015-11-19 KR KR1020177016516A patent/KR102049647B1/ko active IP Right Grant
- 2015-11-19 PH PH12017500935A patent/PH12017500935A1/en unknown
- 2015-11-19 PE PE2017000888A patent/PE20170957A1/es unknown
- 2015-11-19 TW TW104138282A patent/TW201625673A/zh unknown
- 2015-11-19 SG SG10201809427SA patent/SG10201809427SA/en unknown
- 2015-11-19 CA CA3014641A patent/CA3014641C/en active Active
- 2015-11-19 JP JP2017526961A patent/JP6484337B2/ja active Active
- 2015-11-19 US US15/527,363 patent/US20170355743A1/en not_active Abandoned
- 2015-11-19 TN TN2017000178A patent/TN2017000178A1/en unknown
- 2015-11-19 WO PCT/US2015/061445 patent/WO2016081670A2/en active Application Filing
-
2017
- 2017-05-10 ZA ZA2017/03238A patent/ZA201703238B/en unknown
- 2017-05-11 IL IL252257A patent/IL252257A0/en unknown
- 2017-05-18 CO CONC2017/0004976A patent/CO2017004976A2/es unknown
- 2017-05-18 CL CL2017001288A patent/CL2017001288A1/es unknown
- 2017-05-19 MX MX2020014120A patent/MX2020014120A/es unknown
- 2017-05-19 GT GT201700104A patent/GT201700104A/es unknown
- 2017-05-19 DO DO2017000124A patent/DOP2017000124A/es unknown
- 2017-05-19 NI NI201700060A patent/NI201700060A/es unknown
- 2017-05-19 MX MX2020014121A patent/MX2020014121A/es unknown
- 2017-05-19 SV SV2017005445A patent/SV2017005445A/es unknown
-
2018
- 2018-06-13 US US16/007,046 patent/US10183981B2/en active Active
- 2018-07-31 AU AU2018211207A patent/AU2018211207B2/en active Active
- 2018-07-31 AU AU2018211208A patent/AU2018211208B2/en active Active
- 2018-09-28 JP JP2018183314A patent/JP2019014734A/ja not_active Withdrawn
- 2018-09-28 JP JP2018183315A patent/JP6943825B2/ja active Active
- 2018-09-28 JP JP2018183316A patent/JP6703068B2/ja active Active
- 2018-11-26 US US16/199,774 patent/US10800827B2/en active Active
-
2019
- 2019-04-26 CL CL2019001143A patent/CL2019001143A1/es unknown
- 2019-04-26 CL CL2019001144A patent/CL2019001144A1/es unknown
- 2019-11-12 JP JP2019204409A patent/JP6931033B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201700060A (es) | Agonistas parciales del receptor de insulina | |
| UY36179A (es) | Derivados de exendina-4 como agonistas selectivos del receptor de glucagón | |
| ECSP17015977A (es) | Terapia de combinacion | |
| BR112017012364A2 (pt) | pré-tratamento rápido. | |
| IN2015DE00625A (es) | ||
| FR3023171B1 (fr) | Autoinjecteur. | |
| ES2914082T8 (es) | Procedimiento de generación de progenitores de células T | |
| FR3023170B1 (fr) | Autoinjecteur. | |
| ECSP17039183A (es) | Agonistas parciales del receptor de insulina | |
| EA201991576A1 (ru) | Частичные агонисты инсулинового рецептора | |
| GT201700043S (es) | Pico para lavaplatos | |
| TN2014000468A1 (fr) | اختراع الة للف شباك مراكب الصيد البحري و تسهيل تحويلها من المركب الى رصيف الميناء ثم ارجاعها للمركب بعد القيام بعملية ترقيعها | |
| TN2014000355A1 (fr) | طريقة مبتكرة لتوفير الاضاءة العامة و المنزلية | |
| TN2014000377A1 (fr) | طائرة كهربائية كاتمة للصوت | |
| GT201400039S (es) | Diseño de bici-motocicleta | |
| ITCE20140004U1 (it) | Salvabimbi del dr. cirillo | |
| ES1119305Y (es) | Lámpara de mesa | |
| TN2014000384A1 (fr) | نظام صوتي ذكي وآمن | |
| CR20140455S (es) | Grua de portico | |
| CL2014003446S1 (es) | Mesa. | |
| CR20140458S (es) | Grúa de pórtico | |
| ES1106783Y (es) | Mesa de cultivo | |
| TN2014000388A1 (fr) | منظومة فيزيائية متجانسة كهربائية ميكانيكية مغناطيسية لتوليد الطاقة الكهربائية الحرة الايكولوجية المضاعفة | |
| TN2014000354A1 (fr) | جهاز مبتكر لتلقيح النخيل | |
| GT201400051S (es) | Escúter o motoneta |